UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance
Updated Guidance Setting Out MHRA’s New Licensing Route Welcomed By BBA And IGBA
Executive Summary
Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.
You may also be interested in...
Biosimilar Clinical Trials: How Can Regulators Determine Waiver Early In Development?
The evidence is growing that comparative efficacy trials may not be necessary for all biosimilars, but regulators said they need a standard for sponsors to meet in order to waive them.
Biosimilar Clinical Trials: How Can Regulators Determine Waiver Early In Development?
The evidence is growing that comparative efficacy trials may not be necessary for all biosimilars, but regulators said they need a standard for sponsors to meet in order to waive them.
UK Lucentis Biosimilar Nod Offers Teva Potential First-Mover Advantage
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.